Trademark: 79164550
Word
ARVEN
Status
Dead
Status Code
709
Status Date
Friday, May 5, 2023
Serial Number
79164550
Registration Number
5061369
Registration Date
Tuesday, October 18, 2016
Mark Type
4000
Filing Date
Wednesday, October 1, 2014
Published for Opposition
Tuesday, August 2, 2016
Cancellation Date
Friday, May 5, 2023

Trademark Owner History

Classifications
5 Pharmaceuticals and pharmaceutical preparations for the prevention and treatment of cardiovascular disorders, skeleto-muscular disorders, general infections, viral infections, central nervous system disorders, gastro-intestinal disorders, fungal diseases, allergy, ophthalmic diseases, hemophilia, metabolic diseases, cancer, multiple sclerosis, neutropenia, non-Hodgkin lymphoma, Crohn's Disease, autoimmune disorders, urologic diseases, sexual dysfunction, osteoporosis, and climacteric diseases; pharmaceutical preparations, namely, anticoagulants and platelet aggregation inhibitors, contraceptive preparations, analgesics, anti-pyretics, anti-inflammatory preparations, anti-septic preparations, medicated lip balm, anesthetic spray for topical use, astringents, pediculicides, decongestants, antifungal agents, anti-infective pharmaceutical preparations, antacids, cold preparations in the nature of preparations for treating colds, menstrual symptom treatment preparations and dermatologicals; Pharmaceuticals and pharmaceutical preparations, namely, dry powder inhalers filled with pharmaceutical preparations for the treatment of asthma and respiratory diseases; Inhalation products, namely, inhalers filled with pharmaceutical preparations for the treatment of asthma, respiratory diseases; pharmaceutical preparations used in medical diagnostic procedures, namely, contrast media for use with x-ray, magnetic resonance and ultrasound equipment; veterinary preparations for medical use, namely, anesthetics, combination sedative, analgesic; veterinary preparations for medical use for the treatment of bacterial infections; pharmaceutical preparations, namely, Systemic anti-infectives, namely, antibacterial and antifungal pharmaceuticals; mineral preparations, namely, vitamin and mineral supplements, vitamin and mineral preparations for medical use, vitamin preparations and mineral supplements; Musculo-skeletal system pharmaceutical products for the treatment of musculo-skeletal system diseases; Cardiovascular pharmaceuticals, namely, diuretics, lipid lowering agents, beta blocking agents, calcium antagonists and cardiovascular treatment preparations and cardiovascular agents for medical purposes; Pharmaceuticals for the prevention and treatment of disorders of the nervous system, namely, analgesics, psychoanaleptics, psycoleptics, anti-epileptics, central nervous system drugs, anaesthetics, antiparkinson preparations; Pharmaceuticals for the treatment of respiratory diseases and asthma; Dermatological pharmaceutical products; Pharmaceuticals for the treatment of hormonal disorders and the prevention of osteoporosis; Anti-diabetic pharmaceuticals; Pharmaceuticals for the treatment of bone diseases and joint diseases; Pharmaceuticals for the treatment of viral and infectious diseases; Pharmaceuticals for use as antineoplastic agents; Pharmaceuticals for the treatment of immune system related diseases and disorders; Pharmaceuticals for the treatment of kidney diseases; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals for ophthalmological use; pharmaceutical preparations for the treatment of cardiovascular disorders, skeleto-muscular disorders, general infections, viral infections, central nervous system disorders, gastro-intestinal disorders, fungal diseases, erectile dysfunction, respiratory diseases, allergy, ophthalmic diseases, containing one or more of the following active ingredients - cromolin sodium, amlodipin besylate, alendronate sodium, chlorazepate dipotassium, atropine sulphate, atorvastatin calcium, candesartan cilexetil, ceftriaxone sodium, ephedrine hcl, guaiphenesine, zafirlukast, donepezil hcl, diflunisal, dipyridamole, famotidine, losartan potassium, hydro-chlorothiazide, meloxicam, phenyleprine hcl, fexofenadine hcl, indapamide, sulfisoxazole, clopidogrel, lansoprazole, clarithromycin, flurbiprofen, nimesulide, pantoprazole, paracetamole, pilocarpine hcl, lisinopril, pseudoephedrine hcl, ciprofloxacin hcl, sertraline hcl, cyclopentolate hcl, dihydroergotoxine methansulfonate, terbinafine, timolol maleate, tiamphenicol, azithromycin, tenoxicam, fluconazole, digoxine, tioconazole, dimenhydrinate, quinidine arabogalactane sulphate, quinidine phenylethyl barbiturate, diltiazem hcl, buspirone hcl, amiodarone hcl, trazodone, difluprednate, enoxacin, lactulose, ketorolac, pentoxifylline, vitamin e, chlorhexidine, cetrimide, propyphenazone, caffeine, cetirizine, phenylpropanolamine, zolpidem, bacampicillin hcl, roxithromycin, sultamicillin tosilate, acetylsalicylic acid, ampicillin na, sulbactam na, sildenafil citrate, ambroxol hcl, ribavirin, loratadine, etodolac, omeprazole, oxybutynin chloride, quinidine sulphate, olanzapine, raloxifen, pioglitazone, moxifloxacin, rosiglitazone, sibutramin, carvedilol, montelukast, citalopram, gliclazide, cefaclor, ezetimibe, rofecoxib, quetiapine fumarate, metformin hcl, acarbose, chlorpheniramine maleate, nateglinide, leflunomide, valsartan, cefazolin sodium, diacerein, paroxetine, levofloxacin, levetiracetam, zolmitriptan, glibenclamide, tizanidine, perindopril erbumine, ramipril, ceftazidime, cefuroxime axetyl, thiocolchicoside, acamprosate, acetylcysteine, alpha calcidol, alpha lipoic acid, aripiprazole, atomoxetine, balsalazide disodium, butenafine hcl, calcitriol, carbonyl iron, folic acid, calcium carbonate, magnesium hydroxide, cefdinir, cefepime hcl, cefixime, cefpodoxime proxetil, cefprozil, cephalexine monohydrate, ciclesonide, cilazapril, cilostazol, cinitapride, citicoline, co-enzyme q10, darifenasin, deferiprone, dothiepin, duloxetine, eletriptan, escitalopram, esomeprazole, etoricoxib, felodipine, fenofibrate, ferrous sulphate, zinc sulphate, fluvastatin, frovatriptan, gabapentin, galantamine, gemifloxacin, ginkgo biloba, glimepride, granisetron, ibandronate, irbesartan, iron hydroxide polymaltose, lamivudine, lamotrigine, levetiracetam, letrozole, linezolide, memantine hcl, metoprolol, midodrine, mirtazapine, mizolastine, mosapride citrate dihydrate, mycophenolate mofetil, nebivolol, nefazodone, niacin, nitazoxanide, ondansetron, ornidazole, oxcarbazepine, pimecrolimus, pravastatin, pregabalin, rabeprazol, rebamipide, repaglinide, risedronate, risperidone, rivastigmine, rosuvastatin, saccharomyces boulardii, tacrolimus, tadalafil, tamsulosin hcl, tazaroten, tazobactam sodium, piperacillin sodium, tegaserod, telithromycin, terazocin, teriparatide, tolterodine tartrate, topiramate, trandolapril, trimethazidine, valacyclovir, valproate sodium, venlafaxine, voriconazole, ximelagatran, zaleplon, ziprasidone, zoledronic acid
The wording "ARVEN" has no meaning in a foreign language.

Trademark Events
Feb 5, 2024
Total Invalidation Processed By The Ib
Jan 17, 2024
Generic Madrid Transaction Sent To Ib
Jan 17, 2024
Generic Madrid Transaction Created
Jan 5, 2024
Total Invalidation Of Reg Ext Protection Created
May 5, 2023
Cancelled Section 71
Oct 18, 2021
Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed
May 7, 2020
New Representative At Ib Received
Jan 25, 2018
New Representative At Ib Received
Jul 14, 2017
Final Decision Transaction Processed By Ib
Feb 23, 2017
Generic Madrid Transaction Sent To Ib
Feb 23, 2017
Generic Madrid Transaction Created
Jan 18, 2017
Final Disposition Notice Created, To Be Sent To Ib
Nov 18, 2016
Notification Of Possible Opposition - Processed By Ib
Oct 18, 2016
Registered-Principal Register
Oct 12, 2016
Notification Of Possible Opposition Sent To Ib
Oct 12, 2016
Notification Of Possible Opposition Created, To Be Sent To Ib
Aug 12, 2016
Notification Of Possible Opposition - Processed By Ib
Aug 2, 2016
Official Gazette Publication Confirmation E-Mailed
Aug 2, 2016
Published For Opposition
Jul 13, 2016
Notification Of Possible Opposition Sent To Ib
Jul 13, 2016
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Jul 13, 2016
Notification Of Notice Of Publication E-Mailed
Jun 29, 2016
Law Office Publication Review Completed
Jun 23, 2016
Approved For Pub - Principal Register
Jun 23, 2016
Examiner's Amendment Entered
Jun 23, 2016
Notification Of Examiners Amendment E-Mailed
Jun 23, 2016
Examiners Amendment E-Mailed
Jun 23, 2016
Examiners Amendment -Written
Jan 5, 2016
Notification Of Final Refusal Emailed
Jan 5, 2016
Final Refusal E-Mailed
Jan 5, 2016
Final Refusal Written
Dec 15, 2015
Teas/Email Correspondence Entered
Dec 15, 2015
Correspondence Received In Law Office
Dec 10, 2015
Assigned To Lie
Nov 30, 2015
Assigned To Lie
Nov 12, 2015
Teas Response To Office Action Received
Jun 2, 2015
Refusal Processed By Ib
Jun 1, 2015
Attorney/Dom.Rep.Revoked And/Or Appointed
Jun 1, 2015
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
May 15, 2015
Application Filing Receipt Mailed
May 13, 2015
Non-Final Action Mailed - Refusal Sent To Ib
May 13, 2015
Refusal Processed By Mpu
May 13, 2015
Non-Final Action (Ib Refusal) Prepared For Review
May 12, 2015
Non-Final Action Written
May 11, 2015
Assigned To Examiner
May 11, 2015
New Application Office Supplied Data Entered
May 7, 2015
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24